Clinical Trials Browser

Rectal Neoplasms

Colonic Neoplasms

Carcinoma, Hepatocellular

Colorectal Neoplasms

Pancreatic Neoplasms

Carcinoma, Hepatocellular

Cholangiocarcinoma

Esophageal Neoplasms

Appendiceal Neoplasms, Neoplasm Metastasis

Carcinoma, Hepatocellular

Gastric Adenocarcinoma

Carcinoma, Hepatocellular

Locally Advanced Rectal Cancer

Uterine Cervical Neoplasms, Esophageal Neoplasms, Endometrial Neoplasms

Stomach Neoplasms

Stomach Neoplasms

Rectal Neoplasms

Pancreatic Neoplasms

Carcinoma, Hepatocellular

Pancreatic Neoplasms

Carcinoma, Hepatocellular, Recurrence

Metastatic Gastroesophageal Junction Adenocarcinoma

Colorectal Neoplasms

Locally Advanced Rectal Cancer (LARC)

Adenocarcinoma, Stomach Neoplasms

Stomach Neoplasms

Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms

Neoplasms, Stomach Neoplasms

Colorectal Cancer Metastatic

Stomach Neoplasms

Colorectal Neoplasms

Advanced Intrahepatic Cholangiocarcinoma

Stomach Neoplasms

Localized Advanced Rectal Adenocarcinoma

Pancreatic Cancer Metastatic

Pancreatic Cancer Resectable

Colorectal Neoplasms

Carcinoma, Hepatocellular

Cholangiocarcinoma

Liver Metastases

Ovarian Neoplasms, Stomach Neoplasms, Colorectal Neoplasms

Microsatellite Stable Metastatic Colorectal Cancer

Cholangiocarcinoma

Colorectal Neoplasms

Pancreatic Neoplasms

Rectal Neoplasms

Pancreatic Neoplasms

Rectal Neoplasms

Pancreatic Neoplasms

Clinical Trials

SCRT-NALIRIXELOX+Sintilimab as TNT for High-Risk LARC

TRIUNITE-08

A Study of AK112 in Patients With Advanced Hepatocellular Carcinoma (HCC)

Combination With Sintilimab and XELOX+Bevacizumab as 1st Line Therapy in RAS-mutant Metastatic Colorectal Cancer

XH001 Combination With Immunocheckpoint Inhibitor and Chemotherapy for Patients With Resected Pancreatic Cancer

Sintilimab Combined With Bevacizumab Biosimilar as Adjuvant Treatment After Resection of Ruptured Hepatocellular Carcinoma (CLEAR-2)

HAIC Combined With Donafenib and Sintilimab for Unresectable ICC

ESO-Nanjing7

Surufatinib and Sintilimab in Combination With Capecitabine for Metastatic Adenocarcinoma of Small Intestine or Appendix Carcinoma

Radiotherapy Combined With QL1706 and Bevacizumab for Unresectable Non-metastatic Hepatocellular Carcinoma

ARTEMIS-GC3

ICIs and Anti-VEGF Antibody/TKIs With or Without Interventional Therapy for Advanced HCC

NLCCRIT-LARC

Afuresertib +Sintilimab+Chemotherapy in Patients With Selected Solid Tumors That Resistance to Prior Anti-PD-1/PD-L1

Conversion Therapy of Fruquintinib in Combination With Sintilimab and SOX in Unresectable Gastric Cancer

Remission

A Single-Center, Single-Arm Study of Neoadjuvant Short-Course Radiotherapy With IL-2 Followed by Sequential Immunotherapy With CAPOX Combined With PD-1 Antibody and IL-2 for Locally Advanced Rectal Cancer

Surufatinib Combined With Sintilimab and AG in First-line Therapy of Patients With Locally Advanced or Metastatic Pancreatic Cancer

Perioperative Sintilimab Plus Bevacizumab Biosimilar and TACE-HAIC for HCC Patients With PVTT: A Phase-2 Clinical Trial

Sintilimab Combined With Chemotherapy and Radiotherapy in Patients With Inoperable Pancreatic Cancer

Adjuvant Sintilimab Plus Lenvatinib for HCC Characterized With VETC Following Liver Resection

Fruquintinib in Combination With Sintilimab and CAPEOX as First-line Treatment for G/GEJ Cancer

Fruquintinib Combined With Sintilimab ± Radiotherapy for Third-line Treatment of Colorectal Cancer With Liver Metastases

STELLARIII

NeoRacing

IBI343 Combined With Sintilimab Plus Chemotherapy in Gastric Cancer

Efficacy and Safety of Preoperative Sintilimab Plus Nab-paclitaxel and Cisplatin in BR-ESCC Patients

PD-1 Inhibitor Combined With Neoadjuvant Chemoradiotherapy Plus Surgery for Locally Advanced ESCC (NEOCRTEC2101)

YOUNG-NEOS

Exploring Sintilimab + Bevacizumab + Decitabine for Advanced pMMR/MSS Colorectal Cancer (After 2+ Prior Therapies）

Efficacy and Safety of Fruquintinib Combined With Sintilimab and Stereotactic Body Radiation Therapy (SBRT) for the Second-line and Higher-line Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma With Oligometastatic Progression

SPARKLE-L

Personalized Tumor Neoantigen mRNA Therapy for Advanced Intrahepatic Cholangiocarcinoma

Neoadjuvant Apatinib Combined With Sintilimab and Perioperative SOX Versus Neoadjuvant Sintilimab Combined With Perioperative SOX for Intestinal Type of Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma

Intestinal Microbiota Transplantation, Radiochemotherapy and Sintilimab in Localized Advanced Colon Cancer

Personalized Tumor Neoantigen MRNA Therapy for Advanced Pancreatic Cancer.

Personalized Tumor Neoantigen MRNA Therapy Adjuvant Treatment for Postoperative Pancreatic Cancer.

Different Cycles of Preoperative Neoadjuvant Sintilimab in Mismatch-repair Deficient/microsatellite Instability-high, Locally Advanced Colorectal Cancer

TACE Combined with Anti-PD-1 Antibody in Patients with Advanced Hepatocellular Carcinoma

Lenvatinib Plus Sintilimab in Patients With Immune Checkpoint Inhibitor Previously Treated Advanced Liver Cancer

Cryoablation Combined with Sintilimab Plus Regorafenib in Previously Treated Colorectal Cancer Liver Metastasis

Study of Intratumoral IVX037 in Patients With Advanced or Metastatic Solid Tumours

iPULSAR-CRC

Cryoablation Combined With Sintilimab Plus Lenvatinib in Patients With Advanced Intrahepatic Cholangiocarcinoma

Regorafenib and Sintilimab in Combination with Electroacupuncture in MSS CRC

Neoadjuvant/Adjuvant Sintilimab, Nab-paclitaxel, and Gemcitabine for Resectable/Borderline Resectable Pancreatic Cancer

PICS

CISPD-7

CASINOs

mFOLFIRINOX Plus Anlotinib and Sintilimab for Advanced Pancreatic Cancer